[1]刘光华,夏 芳,欧阳强.肝动脉化疗栓塞对肝细胞癌切除术后预防复发的研究[J].介入放射学杂志,2015,(02):125-129.
　LIU Guang hua,XIA Fang,OUYANG Qiang..The effect of transcatheter arterial chemoembolization on the prevention of recurrence in hepatocellular carcinoma following hepatectomy[J].journal interventional radiology,2015,(02):125-129.
点击复制

肝动脉化疗栓塞对肝细胞癌切除术后预防复发的研究 ()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2015年02期
页码:
125-129
栏目:
肿瘤介入
出版日期:
2015-02-25

文章信息/Info

Title:
The effect of transcatheter arterial chemoembolization on the prevention of recurrence in hepatocellular carcinoma following hepatectomy
作者:
刘光华;  夏 芳;  欧阳强
Author(s):
LIU Guang hua;  XIA Fang;  OUYANG Qiang.
Department of Interventional Radiology， Affiliated Xinhua Hospital， School of Medicine， Shanghai Jiaotong University， Shanghai 200092， China
关键词:
【关键词】 肝细胞癌;  肝切除;  预防性;  肝动脉化疗栓塞术;  复发
文献标志码:
A
摘要:
【摘要】 目的 探讨预防性TACE对原发性肝细胞癌（HCC）根治性切除术后复发的影响。方法 回顾性分析2008年5月—2012年3月行根治性切除并经病理学确诊的557例HCC患者，根据术后2个月内是否行预防性TACE分为两组：预防性介入组（n = 327）和未施预防性介入组（n = 230），分析两组间的一般临床病理资料的差异，利用Kaplan Meier计算复发时间，log rank检验评估不同组别患者的复发差异，采用Cox比例风险模型分析HCC术后复发的独立危险因素，并对相关独立危险因素按是否接受预防性介入进行分层分析。结果 两组患者在一般临床病理资料比较差异无统计学意义。经Cox比例风险模型多因素分析发现，年龄（≤ 50岁）、血清甲胎蛋白（AFP，> 20 ng/ml）水平、肿瘤直径（> 5 cm）、手术切缘（< 1 cm）、微血管癌栓（MVI）以及术后行预防性TACE是影响HCC术后复发的独立危险因素。进一步分层分析，上述5个因素的患者中，预防性TACE组的复发率较未预防性TACE组低且差异有统计学意义。结论 HCC根治性切除术后，预防性TACE可降低肝癌的总体复发率；对于肝癌确诊年龄小、术前AFP阳性、肿瘤直径 > 5 cm、手术切缘 < 1 cm和有MVI的HCC患者，预防性TACE可显著降低术后的复发率。

参考文献/References:

［1］ Jemal A, Bray F, Center MM, et al. Global cancer statistics［J］. CA Cancer J Clin, 2011, 61: 69 90.
［2］ Xia Y, Qiu Y, Li J, et al. Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial［J］. Ann Surg Oncol, 2010, 17: 3137 3144.
［3］ Xi T, Lai EC, Min AR, et al. Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: a non randomized comparative study［J］. Hepatogastroenterology, 2012, 59: 1198 1203.
［4］ Choi JW, Park JY, Ahn SH, et al. Efficacy and safety of transarterial chemoembolization in recurrent hepatocellular carcinoma after curative surgical resection［J］. Am J Clin Oncol, 2009, 32: 564 569.
［5］ Kim do Y, Ahn SH, Kim SU, et al. Adjuvant hepatic arterial infusional chemotherapy with 5 fluorouracil and cisplatin after curative resection of hepatocellular carcinoma［J］. Oncology, 2011, 81: 184 191.
［6］ 肖运平， 肖恩华． 介入治疗在防治肝癌术后复发中的作用及进展［J］． 介入放射学杂志， 2008， 17： 831 834．
［7］ 奚 韬， 闫振林， 王 葵， 等． 术后经导管动脉化疗栓塞对不同病理特征肝癌的抗复发作用［J］． 中华外科杂志， 2007， 45： 587 590．
［8］ Wang K, Liu J, Yan ZL, et al. Overexpression of aspartyl (asparaginyl) beta hydroxylase in hepatocellular carcinoma is associated with worse surgical outcome［J］. Hepatology, 2010, 52: 164 173.
［9］ Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48 900 necropsies［J］. Cancer, 1954, 7: 462 503.
［10］ Bruix J, Sherman M. Management of hepatocellular carcinoma［J］. Hepatology, 2005, 42: 1208 1236.
［11］ Takeishi K, Shirabe K, Muto J, et al. Clinicopathological features and outcomes of young patients with hepatocellular carcinoma after hepatectomy［J］. World J Surg, 2011, 35: 1063 1071.
［12］ Kim BK, Ahn SH, Seong JS, et al. Early α fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma［J］. Liver Int, 2011, 31: 369 376.
［13］ Tangkijvanich P, Anukulkarnkusol N, Suwangool P, et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha fetoprotein levels［J］. J Clin Gastroenterol, 2000, 31: 302 308.
［14］ Jeng KS, Jeng WJ, Sheen IS, et al. Is less than 5 mm as the narrowest surgical margin width in central resections of hepatocellular carcinoma justified［J］. Am J Surg, 2013, 206: 64 71.
［15］ Tang YH, Wen TF, Chen X. Resection margin in hepatectomy for hepatocellular carcinoma: a systematic review［J］. Hepatogastroenterology, 2012, 59: 1393 1397.
［16］ Sumie S, Kuromatsu R, Okuda K, et al. Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors［J］. Ann Surg Oncol, 2008, 15: 1375 1382.
［17］ Lim KC, Chow PK, Allen JC, et al. Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria［J］. Ann Surg, 2011, 254: 108 113.

相似文献/References:

[1]姚雪松,李 槐.不可手术切除的肝细胞癌的疗效评价标准——改良ＲＥＣＩＳＴ标准更可靠[J].介入放射学杂志,2012,(03):177.
　. Ｔｈｅｒａｐｅｕｔｉｃ ｅｖａｌｕａｔｉｏｎ ｃｒｉｔｅｒｉｏｎ ｏｆ ｉｎｏｐｅｒａｂｌｅ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ： ｍｏｄｉｆｉｅｄ ＲＥＣＩＳＴ ａｓ ａ ｍｏｒｅ ｒｅｌｉａｂｌｅ ｓｔａｎｄａｒｄ[J].journal interventional radiology,2012,(02):177.
[2]梁茂全,苏洪英. 肝癌化疗栓塞前后甲胎蛋白变化模式的临床意义[J].介入放射学杂志,2012,(04):333.
　.Ｔｈｅ ｔｒａｎｓｆｏｒｍａｔｉｏｎ ｐａｔｔｅｒｎ ｏｆ ｓｅｒｕｍ аｆｅｔｏｐｒｏｔｅｉｎ ａｆｔｅｒ ｔｒａｎｓｃａｔｈｅｔｅｒ ａｒｔｅｒｉａｌ ｃｈｅｍｏｅｍｂｏｌｉｚａｔｉｏｎ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａ： ｉｔｓ ｃｌｉｎｉｃａｌ ｓｉｇｎｉｆｉｃａｎｃｅ [J].journal interventional radiology,2012,(02):333.
[3]孙 磊,施海彬,刘 圣,等.肝细胞癌肝动脉门静脉分流形成的相关因素分析[J].介入放射学杂志,2012,(03):206.
　,,et al.Ｔｈｅ ｆａｃｔｏｒｓ ｒｅｌａｔｅｄ ｔｏ ｔｈｅ ｆｏｒｍａｔｉｏｎ ｏｆ ａｒｔｅｒｉｏｐｏｒｔａｌ ｓｈｕｎｔｉｎｇ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ [J].journal interventional radiology,2012,(02):206.
[4]沈海洋,刘瑞宝,刘 岩,等. 肝右叶前、后段原发性肝癌TACE后VEGF及CD34的表达水平 ；[J].介入放射学杂志,2012,(06):469.
　SHEN Hai- yang,LIU Rui- bao,LIU Yan,et al. The expression levels of vascular endothelial growth factor and CD34 in residual cancerous tissues of primary hepatocellular carcinoma located at anterior and posterior segments of right lobe liver after TACE[J].journal interventional radiology,2012,(02):469.
[5]李晓峰,钱国军,张 磊,等. 微波高功率条件下消融原发性肝癌的初步研究[J].介入放射学杂志,2011,(12):974.
　LI Xiao-feng,QIAN Guo-jun,ZHANG Lei,et al.Microwave ablation with high output power for the treatment of hepatocellular carcinoma: a preliminary study[J].journal interventional radiology,2011,(02):974.
[6]彭辽河,胡晓燕,李 杰,等. 18F-FDG PET/CT显像在肝细胞癌TACE术后残留或复发病灶检出中的应用价值[J].介入放射学杂志,2012,(08):636.
　PENG Liao- he,HU Xiao- yan,LI Jie,et al. Clinical application of 18F- FDG PET/CT imaging in detecting residual lesions or recurrence foci of hepatocellular carcinoma after TACE treatment[J].journal interventional radiology,2012,(02):636.
[7]陆小华,朱小庆,茅国新.肝细胞癌相关单核苷酸多态性的研究进展[J].介入放射学杂志,2013,(06):520.
　LU Xiao? hua,ZHU Xiao? qing,MAO Guo? xin.. Hepatocellular carcinoma?蛳 related single nucleotide polymorphisms： recent advances in research[J].journal interventional radiology,2013,(02):520.
[8]姚雪松,闫 东,曾辉英,等.TACE联合索拉非尼治疗不能手术切除肝细胞癌介入治疗间隔时间的分析[J].介入放射学杂志,2014,(09):769.
　YAO Xue song,YAN Dong,ZENG Hui ying,et al.TACE combined with sorafenib for inoperable hepatocellular carcinoma： analysis of treatment interval[J].journal interventional radiology,2014,(02):769.
[9]姚雪松,闫 东,曾辉英,等. TACE联合索拉非尼治疗不能手术切除肝细胞肝癌50例[J].介入放射学杂志,2013,(05):381.
　YAO Xue? song,YAN Dong,ZENG Hui? ying,et al. Ttransarterial chemoembolization combined with sorafenib for inoperable hepatocellular carcinoma： a clinical analysis of 50 cases[J].journal interventional radiology,2013,(02):381.
[10]赵 松,陈学春,龙清云,等. 经肝动脉化疗栓塞联合射频消融治疗肝细胞癌疗效荟萃分析[J].介入放射学杂志,2013,(11):908.
　ZHAO Song,CHEN Xue? chun,LONG Qing? yun,et al. Transcatheter arterial chemoembolization combined with radiofrequency ablation for the treatment of hepatocellular carcinoma： a systematic review and Meta analysis[J].journal interventional radiology,2013,(02):908.

备注/Memo

备注/Memo:
（收稿日期：２０１4-０7-０9）
（本文编辑：俞瑞纲 )
更新日期/Last Update: 2015-02-16